Search Results
Your search for ,mEn matches 2741 pages
Showing 1451 - 1500Apalutamide, Enzalutamide Improve Metastasis-Free Survival in Nonmetastatic Castrate-Resistant Prostate Cancer
IN TWO SEPARATE TRIALS presented at the 2018 Genitourinary Cancers Symposium, apalutamide and enzalutamide (Xtandi), respectively, reduced the risk of metastasis and prolonged metastasis-free survival in men with high-risk nonmetastatic castrate-resistant prostate cancer. In the SPARTAN trial,1,2...
New Agents for Initial Treatment of Metastatic Prostate Cancer: A New Standard of Care?
FOR DECADES, the status of metastatic prostate cancer trials was not particularly exciting. With an absence of high-impact novel agents, the focus of cancer trial groups was on the improvement of standard care. Well-crafted, large trials of hormonal therapy demonstrated the utility of combined...
Multimodal Treatment in Patients With Gleason Score 9–10 Prostate Cancer
University of California, Los Angeles (UCLA) researchers have discovered that a combination of high doses of radiotherapy and hormonal therapy provides the best chance of decreasing the mortality rate in men with aggressive prostate cancer. The findings, published by Kishan et al in JAMA, also...
Circulating Tumor DNA and Pseudoprogression in Metastatic Melanoma Treated with Anti–PD-1 Antibodies
In a study reported in JAMA Oncology, Lee et al found that measurement of circulating tumor DNA (ctDNA) can help distinguish between pseudoprogression (radiologic progression prior to response) and true progression in patients with metastatic melanoma receiving anti–programmed cell death ...
Body Mass Index and Outcomes With Targeted Therapy, Immunotherapy, or Chemotherapy in Metastatic Melanoma
In a study reported in The Lancet Oncology, McQuade et al found that obesity was associated with improved outcomes in treatment of metastatic melanoma with targeted therapy or immunotherapy—but not chemotherapy—with a survival benefit appearing to be restricted to obese male patients....
SPARTAN Trial: Metastasis-Free Survival in Nonmetastatic Castration-Resistant Prostate Cancer
As reported by Smith et al in The New England Journal of Medicine, the phase III SPARTAN trial has shown that the androgen receptor inhibitor apalutamide (Erleada) produces significant improvement in metastasis-free survival and time to symptomatic progression vs placebo among men with...
UCLA Scientists Receive NIH Research Grant to Advance Adoption of Focal Laser Therapy for Prostate Cancer
UNIVERSITY OF CALIFORNIA (UCLA) researchers Leonard Marks, MD, and Shyam Natarajan, PhD, will lead a $3.1 million research project grant awarded by the National Institutes of Health to advance the adoption of a promising new technology to treat men with prostate cancer. By helping to increase the ...
Retrospective Analysis Suggests Obesity Associated With Longer Survival for Men With Metastatic Melanoma
OBESE PATIENTS with metastatic melanoma who are treated with targeted or immune therapies live significantly longer than those with a normal body mass index (BMI), according to a study published in The Lancet Oncology of 1,918 patients in 6 independent clinical cohorts.1 This effect—referred to as ...
Combined Medical and Psychological Approach May Help Couples Reclaim Intimacy After Prostate Cancer Treatment
“To what extent do treatments for prostate cancer impact sexual functioning? To a great extent,” Christian Nelson, PhD, Chief, Psychiatry Service, Memorial Sloan Kettering Cancer Center, New York, told participants at the 11th Annual Oncofertility Consortium Conference in Chicago.1 Most men with...
FDA Approves Apalutamide for Nonmetastatic, Castration-Resistant Prostate Cancer
The U.S. Food and Drug Administration (FDA) today approved apalutamide (Erleada) for the treatment of patients with prostate cancer that has not spread, but that continues to grow despite treatment with hormone therapy. This is the first FDA-approved treatment for nonmetastatic,...
2018 SURVIVORSHIP: Therapeutic Sexual Aids Frequently Not Available for Cancer Survivors Who Need Them
Cancer care guidelines recommend that cancer survivors who experience sexual dysfunction after cancer treatment use therapeutic aids to help improve their sexual health. However, a new study of 25 leading cancer centers found that 87% of the centers reported having no sexual aids available on site...
Paul L. Nguyen, MD, on Prostate Cancer: Abstract Roundup
Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he chaired on prostate cancer, which included discussion of daily vs weekly image-guided radiotherapy; a biomarker to predict biochemical failure and metastasis; a comparison of abiraterone or enzalutamide activity; and...
Maha Hussain, MD, on Prostate Cancer: Results From the PROSPER Trial
Maha Hussain, MD, of Northwestern University, discusses phase III findings on enzalutamide in men with nonmetastatic castration-resistant prostate cancer (Abstract 3).
2018 GU CANCERS SYMPOSIUM: Antiandrogenic Therapy in Nonmetastatic Castration-Resistant Prostate Cancer
Results from the phase III PROSPER trial in patients with nonmetastatic castration-resistant prostate cancer were presented by Hussain et al at the 2018 Genitourinary Cancers Symposium (Abstract 3). The results show that the use of enzalutamide (Xtandi) plus androgen-deprivation therapy (ADT)...
Differentiating Cancerous Prostate Tissue From Benign Tissue
Using nuclear medicine, German researchers may have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. The research is highlighted in findings published by Rahbar et al in The Journal of Nuclear Medicine. These new findings demonstrate that...
Possible Link Between Drinking Hot Tea and Increased Chance of Esophageal Cancer in High-Risk Individuals
Esophageal cancer is the eighth most common cancer worldwide, with an estimated 456,000 new cases in 2012, and the sixth most common cause of death from cancer with an estimated 400,000 deaths, according to data from GLOBOCAN, which provides statistics on the incidence and mortality of cancer...
2018 GU CANCERS SYMPOSIUM: Chemotherapy Added to Hormone Therapy for Prostate Cancer Improves Quality of Life
A new analysis of the ongoing STAMPEDE clinical trial found that adding docetaxel to hormone therapy for advanced prostate cancer improves quality of life and lowers the need for subsequent therapy. Docetaxel was also found to be cost-effective. These findings will be presented by James et al at...
2018 GU CANCERS SYMPOSIUM: Apalutamide Delays Prostate Cancer Metastases by More Than 2 Years
Findings from the phase III placebo-controlled SPARTAN trial suggest that apalutamide is an effective treatment for men with nonmetastatic castration-resistant prostate cancer who are at high risk for developing metastatic disease and for whom no approved treatments exist. Men who received...
Incidence of Noncardia Gastric Cancer Increasing Among Americans Under 50
A type of cancer that occurs in the lower stomach has been increasing among some Americans under the age of 50, even though in the general population, the incidence of all stomach cancers has been declining for decades. These findings were published by Anderson et al in the Journal of the National...
Obese Men May Have Higher Risk for Biochemical Recurrence Following Radical Prostatectomy
Among men with prostate cancer who underwent radical prostatectomy, those who were obese had a higher risk of biochemical recurrence, according to data presented at the American Association for Cancer Research (AACR) Special Conference on Obesity and Cancer: Mechanisms Underlying Etiology and...
Fox Chase Announces Winners of ACS Institutional Research Grant for Junior Investigators
Fox Chase Cancer Center and the Lewis Katz School of Medicine are pleased to announce the winners of its American Cancer Society (ACS) Institutional Research Grant Pilot Project Competition for Junior Investigators. The competition was open to eligible junior faculty at Fox Chase Cancer Center and ...
Internationally Renowned Prostate Cancer Expert Gerald E. Hanks, MD, Dies
FROM WILHELM RÖNTGEN’S groundbreaking discovery of x-rays in 1895, the history of radiotherapy has been rich with colorful paradigm-changing researchers and physicians who over the past century have transformed the field into one of the pillars of cancer treatment. One such trailblazer who...
Second Global AYA Cancer Congress Highlights Research Advances and the Global Burden of Cancer Among Young Adults
This past December, nearly 400 medical professionals from a variety of fields—including medical oncology, palliative care, science, nursing, social work, and psychology—and 23 countries traveled to Atlanta, to attend the 2nd Global Adolescent & Young Adult (AYA) Cancer Congress. The 3-day...
Pomegranates and Other Polyphenols: New Evidence to Share With Prostate Cancer Patients
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, Channing Paller, MD, explores the role of pomegranate- and grape-based...
Cancer Statistics, 2018: U.S. Cancer Mortality Continues Decades-Long Drop
THE CANCER death rate dropped 1.7% from 2014 to 2015, continuing a drop that began in 1991 and has reached 26%, resulting in nearly 2.4 million fewer cancer deaths during that time. The data are reported in “Cancer Statistics, 2018,” the American Cancer Society’s comprehensive annual report on...
Preserving Sexual Function in Women Treated for Cancer
“There is huge potential to positively influence a patient’s experience and outcomes” by addressing concerns about sexual function after cancer treatment early in the course of treatment planning, Stacy Tessler Lindau, MD, MA, stated in her keynote address at the 11th Annual Oncofertility...
Celebrating the Life of Jimmie Holland, MD
The oncology community mourns the sudden passing of Jimmie C. Holland, MD, who died on December 24, 2017, at the age of 89. Dr. Holland’s achievements over her 40-year career are legend. They include the founding of the subspecialty of psycho-oncology, the establishment of a full-time Psychiatry...
CAP Guideline Details HPV Testing in Head and Neck Carcinomas
Patients with certain head and neck cancers who test positive for high-risk types of human papillomavirus (HPV) have a better prognosis and may need less aggressive treatment. To help ensure that patients with these cancers are accurately diagnosed and effectively treated, the College of...
Bipolar Androgen Therapy After Progression on Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
In a single-center phase II study reported in The Lancet Oncology, Teply et al found that bipolar androgen therapy can induce prostate-specific antigen (PSA) response and resensitization to enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer who progressed on...
Age-Associated Mortality Risk and BRAF V600E Status in Papillary Thyroid Cancer
In a study reported in the Journal of Clinical Oncology, Shen et al found evidence that BRAF V600E mutation status explains the long-recognized increased mortality risk associated with age at diagnosis in patients with papillary thyroid cancer. Study Details The study involved data from 2,638...
Cancer Statistics 2018: U.S. Cancer Mortality Continues Decades-Long Drop
The cancer death rate dropped 1.7% from 2014 to 2015, continuing a drop that began in 1991 and has reached 26%, resulting in nearly 2.4 million fewer cancer deaths during that time. The data is reported in “Cancer Statistics, 2018,” the American Cancer Society’s...
Association of Systemic Inflammation and Sarcopenia With Survival in Colorectal Cancer
Results from the C SCANS (Colorectal Cancer: Sarcopenia, Cancer, and Near-Term Survival) study indicate that prediagnosis systemic inflammation and at-diagnosis sarcopenia are associated with an increased mortality risk in patients with nonmetastatic colorectal cancer. The findings were reported...
Expect Questions About Link Between Alcohol and Cancer
With headlines such as “Cutting back on alcohol can prevent cancers”1 and “Even light drinking may raise your cancer risk,”2 media reports may be generating questions from patients about the ASCO statement summarizing evidence linking alcohol to an increased risk of cancer.3 “What I personally...
Oncologists Urged to Be Proactive in Advising Patients to Reduce Risk of Alcohol-Related Cancers
A recently released ASCO statement summarizing extensive evidence linking alcohol use to an increased risk of several leading cancers, including breast, colon, and head and neck, called on oncologists “as front-line providers for cancer patients” to help patients reduce excessive alcohol use.1...
Providing a Safe Haven for Patients With Advanced Lung Cancer
In 1996, Jimmie C. Holland, MD, the Wayne E. Chapman Chair in Psychiatric Oncology at Memorial Sloan Kettering Cancer Center (MSK) in New York, decided to launch the cancer center’s Lung Cancer Survivorship Program after she had a startling encounter with a patient. “The woman said to me, ‘Would...
Lung Cancer in Never Smokers: A Complex Clinical Phenomenon
Despite advances in prevention, early detection, and treatments, lung cancer remains the leading cause of cancer-related death in the United States. Although cigarette smoking is the main cause of lung cancer, about 10% of these patients are lifelong never smokers for whom the molecular...
Front-Line Brentuximab Plus AVD vs Standard ABVD in Advanced Hodgkin Lymphoma
FRONT-LINE TREATMENT of advanced Hodgkin lymphoma with brentuximab vedotin (Adcetris) plus doxorubicin/ vinblastine/dacarbazine (A+AVD) achieved superior outcomes compared with the standard four-drug regimen of doxorubicin/bleomycin/vinblastine/dacarbazine (ABVD). The substitution of brentuximab...
Alexander Fleming Would Have Loved Our Success With Cancer Immunotherapy
THE UNIVERSITY of Edinburgh Medical School was established in 1726 during the Scottish Enlightenment. As one of the oldest medical schools in the English-speaking world, it is interesting to reflect on the seminal contributions made centuries ago by several alumni that are still relevant to the...
Sexual Problems and Cancer: ASCO Clinical Practice Guideline Adaptation of CCO Guideline
As reported in the Journal of Clinical Oncology by Jeanne Carter, PhD, of Memorial Sloan Kettering Cancer Center, and colleagues, ASCO has issued a clinical practice guideline adaptation of the Cancer Care Ontario (CCO) guideline on interventions to address sexual problems in people with cancer....
California Trends in Cancer Survival by Health Insurance Status
A study using California Cancer Registry data showed that survival improvements in patients with cancer between 1997 and 2014 have largely been limited to those with private or Medicare insurance. These findings were reported in JAMA Oncology by Libby et al. Study Details The study involved...
Study Finds Racial Disparities in Treatment of Clinically Significant Prostate Cancer
In a study reported in the Journal of Oncology Practice, Bickell et al found underuse of treatment for clinically significant prostate cancer was infrequent among white and black patients at two New York City hospitals, but black men accounted for nearly all such underuse of treatment. As noted by...
Study Suggests Racial Differences in Lung Tumor Biology
According to research by the American Cancer Society, lung cancer is the second most common cancer in men and women in the United States and is the leading cause of cancer-related death. In addition, among all populations, African Americans tend to have the highest lung cancer incidence and...
Ibrutinib in Chronic Graft-vs-Host Disease
On August 2, 2017, ibrutinib (Imbruvica) was approved for treatment of adult patients with chronic graft-vs-host disease after failure of one or more lines of systemic therapy.1,2 This is the first U.S. Food and Drug Administration (FDA)-approved therapy for treatment of chronic graft-vs-host...
Born in Chicago, Lymphoma Specialist Sonali M. Smith, MD, Never Left the Windy City
Nationally recognized lymphoma expert Sonali M. Smith, MD, was born and reared in Chicago to a mother who was a pediatrician and allergist, and a father who was an engineer. Her parents were first-generation immigrants from India who placed the value of education second to none. “I became used to...
Obinutuzumab-Based First-Line Treatment Improves Progression-Free Survival vs Rituximab-Based Treatment in Follicular Lymphoma
In the phase III GALLIUM trial reported in The New England Journal of Medicine by Robert Marcus, MBBS, of University College London, and colleagues, obinutuzumab (Gazyva)-based therapy significantly prolonged progression-free survival vs rituximab (Rituxan)-based therapy in patients with previously ...
Vemurafenib in Erdheim-Chester Disease
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 6, 2017, vemurafenib (Zelboraf) was granted...
Cancer and Obesity: Not Such a Linear Relationship
Obesity has been established as a strong risk factor for the development of cancer. African Americans and Hispanics are particularly at risk, and their access to health care is often poor. How do racial and ethnic disparities in the development of obesity as well as access to care intersect to...
HPV Vaccination and Oral HPV Infections in Young Adults in the United States
In a study reported in the Journal of Clinical Oncology, Chaturvedi et al found that whereas prophylactic human papillomavirus (HPV) vaccination has reduced the incidence of oral HPV infection in young adults compared with no vaccination, low uptake of the vaccine has resulted in a modest overall...
Link Between Cancer and Diabetes, High Body Mass Index
According to the International Agency for Research on Cancer and the World Cancer Research Fund, there is a causal association between a high body mass index (BMI) and 14 cancers, including colorectal, gallbladder, pancreatic, kidney, liver, endometrial, postmenopausal breast, ovarian, gastric...
Health-Related Quality of Life With Immediate vs Delayed ADT in Prostate Cancer
In a health-related quality-of-life study among patients in the phase III TOAD trial, immediate vs delayed androgen-deprivation therapy (ADT) was associated with early worsening of androgen-deprivation therapy–related symptoms but few other comparative adverse effects on functioning or quality of...
